NCT01387958View on ClinicalTrials.gov

A Two Week Dosing Study to Determine the Safety and Antiviral Activity of LCQ908 in Hepatitis C Patients

PHASE2TerminatedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

February 29, 2012

Study Completion Date

February 29, 2012

Conditions
Hepatitis C
Interventions
DRUG

LCQ908

DRUG

Placebo

Trial Locations (2)

Unknown

Novartis Investigative Site, Auckland

Novartis Investigative Site, Christchurch

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY